The Race Oncology Ltd (ASX: RAC) share price is climbing today on the back of the company’s latest capital raise.
During morning trade, the pharmaceutical company’s shares are up 3.64% to $3.42 apiece.
What did the company announce?
Investors are driving up the Race Oncology share price following the company’s strongly supported share purchase plan (SPP).
According to its release, Race Oncology advised it has successfully completed its SPP, raising $29.7 million after a scale back. This represents around 6.6% of the company’s issued capital as of today. The offer received strong support from 2,340 shareholders, who applied for more than $43.9 million under the SPP.
The retail component of the company’s equity raising efforts will see 9.9 new million shares created at $3 each.
The funds raised will go towards a number of company programs. These include:
- Phase 1b/2 FTO solid tumour clinical trial ($8 million);
- Cardio-protection Phase 2b clinical trial in breast cancer patients ($7.5 million);
- Phase 2 EMD AML/MDS clinical trial in Europe ($9.2 million);
- Improved formulations of Zantrene ($3.2 million);
- Preclinical cardio-protection studies ($1 million); and
- Development of new molecules ($0.8 million).
The SPP shares are expected to be issued today, and be available for trading from tomorrow.
Race Oncology managing director and CEO Phil Lynch commented:
The number of applications reflects enthusiasm for the significant potential of our lead drug Zantrene, and this enables us to implement our planned clinical and drug development plans across the three-pillar program. We move into 2022 in an exceptional position, with many critical, reportable milestones ahead of us.
Race Oncology share price snapshot
The Race Oncology share price has gained more than 97% in the past 12 months and is up by 95% year to date.
Based on today’s price, Race Oncology has a market capitalisation of about $493 million, with 149.54 million shares on issue.
The post Here’s why the Race Oncology (ASX:RAC) share price is edging higher appeared first on The Motley Fool Australia.
Should you invest $1,000 in Race Oncology right now?
Before you consider Race Oncology, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Race Oncology wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
- Here’s why the Race Oncology (ASX:RAC) share price is climbing today
- Why is the Race Oncology (ASX:RAC) share price plunging 12% today?
- Why Bapcor, Mayne Pharma, Race Oncology, and TechnologyOne shares are sinking
- Racing higher: Race Oncology (ASX:RAC) share price jumps 13% on study breakthrough
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/3EgSEiS